Gilead reported 2025 revenue of $29.44 billion and Q1 2026 revenue of $6.96 billion. The thesis turns on whether HIV durability and cash generation can keep funding oncology, inflammation and pipeline expansion while patent, clinical and debt risks stay controlled.
Paid login unlocks company financials, filing timeline, peer comparison, scorecard, and discussion. Valuation remains admin-only while we finalize market-data licensing.
